ACRO BIOMEDICAL CO., LTD.

$ Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000164033422000809 Filed on April 15, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.25K	$95.25K	$18.12K
YoY Change	425.66%	425.66%	1891.21%
Cash & Equivalents	$95.25K	$95.25K	$18.12K
Short-Term Investments
Other Short-Term Assets	$13.17K	$13.17K	$17.23K
YoY Change	-23.56%	-23.56%
Inventory	$0.00	$0.00	$938.0K
Prepaid Expenses	$1.167K		$1.000K
Receivables	$598.0K	$598.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$706.4K	$706.4K	$973.4K
YoY Change	-27.42%	-27.42%	10.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.43K	$50.43K	$24.70K
YoY Change	104.17%	104.17%	-49.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.230K	$4.230K
YoY Change
Total Long-Term Assets	$54.66K	$54.66K	$24.70K
YoY Change	121.3%	121.3%	-53.09%
TOTAL ASSETS
Total Short-Term Assets	$706.4K	$706.4K	$973.4K
Total Long-Term Assets	$54.66K	$54.66K	$24.70K
Total Assets	$761.1K	$761.1K	$998.1K
YoY Change	-23.74%	-23.74%	7.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.20K	$26.20K	$20.00K
YoY Change	31.0%	5.94%	-16.07%
Accrued Expenses	$24.71K	$24.71K	$24.50K
YoY Change	0.86%	0.86%	2.25%
Deferred Revenue
YoY Change
Short-Term Debt	$20.74K	$20.74K	$243.0K
YoY Change	-91.46%	-91.46%	824.47%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$91.65K	$91.65K	$312.2K
YoY Change	-70.64%	-70.64%	179.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.72K	$25.72K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$25.72K	$25.72K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$91.65K	$91.65K	$312.2K
Total Long-Term Liabilities	$25.72K	$25.72K	$0.00
Total Liabilities	$117.4K	$117.4K	$312.2K
YoY Change	-62.4%	-62.4%	133.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.936M		-$238.7K
YoY Change	3225.52%		96.91%
Common Stock	$32.35M		$924.5K
YoY Change	3399.49%		0.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$643.7K	$643.7K	$685.9K
YoY Change
Total Liabilities & Shareholders Equity	$761.1K	$761.1K	$998.1K
YoY Change	-23.74%	-23.74%	7.07%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Location AuditorLocation	Hackensack, New Jersey
CY2021Q4	us-gaap	Cash Cash	95248	USD
CY2020Q4	us-gaap	Cash Cash	18123	USD
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	598000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	938000	USD
CY2021Q4	acbm	Purchase Deposit For Inventory PurchaseDepositForInventory	12000	USD
CY2020Q4	acbm	Purchase Deposit For Inventory PurchaseDepositForInventory	12000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1167	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	706415	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	973353	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50432	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24700	USD
CY2021Q4	acbm	Security Deposits SecurityDeposits	4230	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Assets Assets	761077	USD
CY2020Q4	us-gaap	Assets Assets	998053	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60042000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47760000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	60042	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	47760	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	685868	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	761077	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	998053	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1197500	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	687964	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	26197	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24734	USD
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	20000	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	20000	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	20741	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	242951	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24713	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24500	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	91651	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	312185	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25719	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	117370	USD
CY2020Q4	us-gaap	Liabilities Liabilities	312185	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	acbm	Deferred Stock Compensation DeferredStockCompensation	0	USD
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	0	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	32293530	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	876762	USD
CY2021Q4	acbm	Deferred Stock Compensation DeferredStockCompensation	-23773383	USD
CY2020Q4	acbm	Security Deposits SecurityDeposits	0	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7936482	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-238654	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	643707	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	938000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	528560	USD
CY2021	us-gaap	Gross Profit GrossProfit	259500	USD
CY2020	us-gaap	Gross Profit GrossProfit	159404	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2667903	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	289867	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	5285175	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	7953078	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	289867	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-7693578	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-130463	USD
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	4250	USD
CY2020	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5082	USD
CY2021	us-gaap	Other Expenses OtherExpenses	4250	USD
CY2020	us-gaap	Other Expenses OtherExpenses	5082	USD
CY2021	acbm	Income Loss Before Income Tax Credits IncomeLossBeforeIncomeTaxCredits	-7697828	USD
CY2020	acbm	Income Loss Before Income Tax Credits IncomeLossBeforeIncomeTaxCredits	-135545	USD
CY2021	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	0	USD
CY2020	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-18092	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7697828	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117453	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53838855	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47760000	shares
CY2020	acbm	Imputed Interest On Related Party Loans ImputedInterestOnRelatedPartyLoans	5082	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117453	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	685868	USD
CY2021	acbm	Share Issuance For Services Amount ShareIssuanceForServicesAmount	7651417	USD
CY2021	acbm	Imputed Interest On Related Party Loans ImputedInterestOnRelatedPartyLoans	4250	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7697828	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	643707	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7697828	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117453	USD
CY2021	acbm	Imputed Interest Related Parties ImputedInterestRelatedParties	4250	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7651417	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2021	acbm	Change Of Rou And Lease Liabilities ChangeOfRouAndLeaseLiabilities	200	USD
CY2020	acbm	Change Of Rou And Lease Liabilities ChangeOfRouAndLeaseLiabilities	1915	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-59440	USD
CY2021	acbm	Increase Decrease In Purchase Deposit For Inventory IncreaseDecreaseInPurchaseDepositForInventory	0	USD
CY2020	acbm	Increase Decrease In Purchase Deposit For Inventory IncreaseDecreaseInPurchaseDepositForInventory	-12000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-167	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1463	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	900	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-17464	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	299335	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-199460	USD
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	19641	USD
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	216672	USD
CY2021	acbm	Repayment To Related Parties RepaymentToRelatedParties	241851	USD
CY2020	acbm	Repayment To Related Parties RepaymentToRelatedParties	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-222210	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	216672	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	77125	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	17212	USD
CY2020Q4	us-gaap	Cash Cash	18123	USD
CY2019Q4	us-gaap	Cash Cash	911	USD
CY2021Q4	us-gaap	Cash Cash	95248	USD
CY2020Q4	us-gaap	Cash Cash	18123	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021	acbm	Operating Lease Liabilities OperatingLeaseLiabilities	50432	USD
CY2020	acbm	Operating Lease Liabilities OperatingLeaseLiabilities	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 -ORGANIZATION AND DESCRIPTION OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical Co., Ltd.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s business is the sale of cordyceps related products. Cordyceps is a fungus that is used in traditional Chinese medicine. During the second and third quarters of 2021, the Company engaged consultants to take the initial steps to develop and implement a research and development and marketing program. These consultants are working independently and report to the chief executive officer. The Company cannot give any assurance that the marketing and research development activities will generate any new product or new marketing opportunities or generate any significant revenue.</p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p>
CY2021	acbm	Concentrationsof Credit Risk Policy Text Block ConcentrationsofCreditRiskPolicyTextBLOCK	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents and related party payables that it will likely incur in the near future. The Company places its cash and cash equivalents with financial institutions of high creditworthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits.</p>
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	20000	USD
CY2021	acbm	Statutory Federal Income Tax Rate StatutoryFederalIncomeTaxRate	0.21	pure
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1616544	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-28464	USD
CY2021	us-gaap	Interest Expense InterestExpense	893	USD
CY2020	us-gaap	Interest Expense InterestExpense	1067	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Utilities Operating Expense Taxes UtilitiesOperatingExpenseTaxes	18092	USD
CY2021	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	1615651	USD
CY2020	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	27397	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18092	USD
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2115	USD
CY2021Q3	us-gaap	Security Deposit SecurityDeposit	4230	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24500	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1682296	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	66645	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1682296	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66645	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	19641	USD
CY2020	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	241851	USD
CY2021	acbm	Non Interest Bearing Percentage NonInterestBearingPercentage	0.05	pure
CY2021	acbm	Percentage Of Inputed Interest PercentageOfInputedInterest	0.04	pure
CY2021	acbm	Imputed Interest Related Parties ImputedInterestRelatedParties	4250	USD
CY2020	acbm	Imputed Interest Related Parties ImputedInterestRelatedParties	5082	USD
CY2021Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	20741	USD
CY2020Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	242951	USD
CY2021Q3	us-gaap	Prepaid Rent PrepaidRent	2190	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50432	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24700	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24713	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24500	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25719	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	50432	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	26280	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	26280	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	52560	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	25140	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	26141	USD

Files In Submission

Name	View Source	Status
0001640334-22-000809-index-headers.html	Edgar Link	pending
0001640334-22-000809-index.html	Edgar Link	pending
0001640334-22-000809.txt	Edgar Link	pending
0001640334-22-000809-xbrl.zip	Edgar Link	pending
acbm-20211231.xsd	Edgar Link	pending
acbm-20211231_cal.xml	Edgar Link	unprocessable
acbm-20211231_def.xml	Edgar Link	unprocessable
acbm-20211231_lab.xml	Edgar Link	unprocessable
acbm-20211231_pre.xml	Edgar Link	unprocessable
acro_10k.htm	Edgar Link	pending
acro_10k_htm.xml	Edgar Link	completed
acro_ex311.htm	Edgar Link	pending
acro_ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

ACRO BIOMEDICAL CO., LTD.

2021 Q4 Form 10-K Financial Statement

#000164033422000809 Filed on April 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission